← Back to all trials
Active Not Recruiting
NCT04668885
CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS
Conditions: Refractory Acute Myeloid Leukemia, Relapsed Acute Myelomonocytic Leukemia, Myelodysplastic Syndromes
Sex: All
Ages: 60 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 13
Sponsor: Case Comprehensive Cancer Center
Location: Cleveland Clinic, Case Comprehensive Cancer Center Cleveland Ohio
Summary
The purpose of this study is to evaluate how effective lower doses of CPX-351 are in older participants with relapsed/refractory acute myeloid leukemia (AML) who are not eligible to receive intensive chemotherapy and in participants with myelodysplastic syndromes (MDS) after Hypomethylating Agents (HMA) failure.
Eligibility Criteria
Inclusion Criteria:
* Primary refractory or relapsed AML (defined by 2016 World Health Organization \[WHO\] criteria) patients who are not suitable for or not willing to receive intensive chemotherapy as evaluated by the treating physician. Primary refractory disease is defined as:
* Failure to achieve a CR, CRi, or mLFS (defined as \
Source: ClinicalTrials.gov (NCT04668885). StuddyBuddy aggregates publicly available trial information.
